Immunome-derived vaccines

Immune response to a subset of antigens and epitopes derived from an infectious pathogen may be sufficient for competent protection; immune recognition of every potential epitope derived from the pathogen's genome does not appear to be required. The pneumococcal and hepatitis vaccines, both of which are subunit vaccines, illustrate this premise. Similarly, 'immunome-derived vaccines' are based on the concept that response to the subset of antigens and epitopes that interface with the host immune system (the immunome) and not the whole organism (represented by the proteome or genome) can be sufficient for protection. Competent immune responses to cancer are also probably restricted to the neoplasm's 'immunome', although the set of antigens that drive successful immune response to cancer cells has proven more difficult to uncover. Researchers are now using bioinformatics sequence analysis tools, epitope mapping tools, microarrays and high-throughput immunology assays to discover the components of the immunome, which are then used to compose these new vaccines. At least one immunome-derived vaccine is in clinical trials and many others are in the vaccine pipeline. Due to the rapid improvement of immunoinformatics tools and immunological assays, the era of immunome-derived vaccines has begun.

[1]  Johannes Söllner,et al.  Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Zagursky,et al.  Bioinformatics: how it is being used to identify bacterial vaccine candidates , 2003, Expert review of vaccines.

[3]  Anne S De Groot,et al.  From immunome to vaccine: epitope mapping and vaccine design tools. , 2003, Novartis Foundation symposium.

[4]  Julie McMurry,et al.  Immuno‐informatics: Mining genomes for vaccine components , 2002, Immunology and cell biology.

[5]  Christian Drosten,et al.  Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome , 2003, Science.

[6]  Søren Buus,et al.  Tumor‐associated antigens identified by mRNA expression profiling induce protective anti‐tumor immunity , 2001, European journal of immunology.

[7]  Rolf Apweiler,et al.  A comparison of signal sequence prediction methods using a test set of signal peptides , 2000, Bioinform..

[8]  R. Rappuoli,et al.  Reverse vaccinology, a genome-based approach to vaccine development. , 2001 .

[9]  M. Suhan,et al.  Disruption of an Internal Membrane-Spanning Region in Shiga Toxin 1 Reduces Cytotoxicity , 1998, Infection and Immunity.

[10]  R. Nogarotto,et al.  Genomic Approach for Analysis of Surface Proteins in Chlamydia pneumoniae , 2002, Infection and Immunity.

[11]  Rino Rappuoli,et al.  Reverse Vaccinology and Genomics , 2003, Science.

[12]  G. Schoolnik,et al.  Comparative genomics of BCG vaccines by whole-genome DNA microarray. , 1999, Science.

[13]  Jonathan A. Eisen,et al.  Microbial genome sequencing , 2000, Nature.

[14]  J. Hoffmann,et al.  Toll receptors in innate immunity. , 2001, Trends in cell biology.

[15]  C. Klade.  Proteomics approaches towards antigen discovery and vaccine development. , 2002, Current opinion in molecular therapeutics.

[16]  Jonathan M Gershoni,et al.  The mapping and reconstitution of a conformational discontinuous B-cell epitope of HIV-1. , 2003, Journal of molecular biology.

[17]  R. Lathigra,et al.  Identification and Characterization of a Novel Family of Pneumococcal Proteins That Are Protective against Sepsis , 2001, Infection and Immunity.

[18]  W. Robinson,et al.  Millennium Award Recipient Contribution Proteomics for the Development of Dna Tolerizing Vaccines to Treat Autoimmune Disease , 2022 .

[19]  Ian T. Paulsen,et al.  Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Fraser,et al.  Functional Selection of Vaccine Candidate Peptides from Staphylococcus aureus Whole-Genome Expression Libraries In Vitro , 2003, Infection and Immunity.

[21]  V. Jongeneel.  Towards a cancer immunome database. , 2001, Cancer immunity.

[22]  J. Mattick,et al.  Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. , 2001, Vaccine.

[23]  R. Zagursky,et al.  Application of genomics and proteomics for identification of bacterial gene products as potential vaccine candidates. , 2000, Vaccine.

[24]  D. O'Kane,et al.  Gene expression microarrays: a 21st century tool for directed vaccine design. , 2001, Vaccine.

[25]  Amos Bairoch,et al.  The PROSITE database, its status in 2002 , 2002, Nucleic Acids Res..

[26]  Vladimir Brusic,et al.  Computational immunology: The coming of age , 2002, Immunology and cell biology.

[27]  Obi L. Griffith,et al.  The Genome Sequence of the SARS-Associated Coronavirus , 2003, Science.

[28]  Darren R Flower,et al.  Proteomics in Vaccinology and Immunobiology: An Informatics Perspective of the Immunone , 2003, Journal of biomedicine & biotechnology.